# The Role of Hypoxia as a Selective Pressure for TP53 Mutations

> **NCT03466034** · — · TERMINATED · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 5 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03466034
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-06
- **Primary completion:** 2018-06-19
- **Final completion:** 2019-07-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low numbers of eligible patients and failure to successfully recruit them.
- **Last updated:** 2020-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466034, "The Role of Hypoxia as a Selective Pressure for TP53 Mutations". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03466034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*